ACROBiosystems

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.

To accelerate AI-driven drug discovery, ACROBiosystems bridges AI-driven molecular design and experimental validation through its AIDD-Ready integrated screening and validation platform. Combining application-ready research tools with CHO-Direct™ services for high-throughput antibody screening, expression, purification, and multidimensional characterization, the platform delivers reliable experimental data to accelerate candidate selection and support AI model optimization.